Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer—A Combined In Silico and In Vitro Strategy

Rearranged during transfection (RET) is a tyrosine kinase oncogenic receptor, activated in several cancers including non-small-cell lung cancer (NSCLC). Multiple kinase inhibitors vandetanib and cabozantinib are commonly used in the treatment of RET-positive NSCLC. However, specificity, toxicity, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramesh, Priyanka, Shin, Woong-Hee, Veerappapillai, Shanthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619101/
https://www.ncbi.nlm.nih.gov/pubmed/34834190
http://dx.doi.org/10.3390/pharmaceutics13111775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619101/
https://www.ncbi.nlm.nih.gov/pubmed/34834190
http://dx.doi.org/10.3390/pharmaceutics13111775

Ejemplares similares